Bausch Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH, and what generic alternatives to BAUSCH drugs are available?
BAUSCH has one hundred and seventy-six approved drugs.
There are one hundred and twenty-one US patents protecting BAUSCH drugs.
There are seven hundred and seventy-one patent family members on BAUSCH drugs in fifty-two countries and two hundred and eight supplementary protection certificates in sixteen countries.
Summary for Bausch
| International Patents: | 771 |
| US Patents: | 121 |
| Tradenames: | 155 |
| Ingredients: | 122 |
| NDAs: | 176 |
| Patent Litigation for Bausch: | See patent lawsuits for Bausch |
Drugs and US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | CETACORT | hydrocortisone | LOTION;TOPICAL | 080426-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bausch | APLENZIN | bupropion hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 022108-002 | Apr 23, 2008 | RX | Yes | No | 7,662,407 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Bausch | TIAZAC | diltiazem hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 020401-002 | Sep 11, 1995 | AB4 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bausch
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | 8,877,168 | ⤷ Try a Trial |
| Bausch | VASERETIC | enalapril maleate; hydrochlorothiazide | TABLET;ORAL | 019221-001 | Oct 31, 1986 | 4,472,380*PED | ⤷ Try a Trial |
| Bausch | ELIDEL | pimecrolimus | CREAM;TOPICAL | 021302-001 | Dec 13, 2001 | 6,352,998*PED | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 348 mg | ➤ Subscribe | 2009-09-24 |
| ➤ Subscribe | Cream | 2.5% | ➤ Subscribe | 2014-06-17 |
| ➤ Subscribe | Extended-release Tablets | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | ➤ Subscribe | 2005-08-30 |
| ➤ Subscribe | Rectal Gel | 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL | ➤ Subscribe | 2004-03-23 |
| ➤ Subscribe | Extended-release Tablets | 65 mg and 115 mg | ➤ Subscribe | 2009-11-19 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 2mL pre-filled syringe | ➤ Subscribe | 2008-12-23 |
| ➤ Subscribe | Extended-release Tablet | 105 rng | ➤ Subscribe | 2010-12-28 |
| ➤ Subscribe | Gel | 1.2%/3.75% | ➤ Subscribe | 2015-09-30 |
| ➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2012-10-19 |
| ➤ Subscribe | Gel | 0.04% | ➤ Subscribe | 2010-12-20 |
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
| ➤ Subscribe | Gel | 1.2%/0.025% | ➤ Subscribe | 2010-12-17 |
| ➤ Subscribe | Gel | 0.77% | ➤ Subscribe | 2006-05-10 |
| ➤ Subscribe | Lotion | 0.1% | ➤ Subscribe | 2016-08-31 |
| ➤ Subscribe | Extended-release Tablets | 174 mg | ➤ Subscribe | 2009-09-28 |
| ➤ Subscribe | Cream | 3.75% | ➤ Subscribe | 2012-08-08 |
| ➤ Subscribe | Extended-release Tablets | 522 mg | ➤ Subscribe | 2009-12-24 |
| ➤ Subscribe | For Inhalation Solution | 6 gm/vial | ➤ Subscribe | 2014-05-22 |
| ➤ Subscribe | Extended-release Tablets | 420 mg | ➤ Subscribe | 2005-04-25 |
| ➤ Subscribe | Rectal Gel | 5 mg/mL, 4mL pre-filled syringe | ➤ Subscribe | 2008-12-08 |
| ➤ Subscribe | Extended-release Tablet | 55 mg and 80 mg | ➤ Subscribe | 2010-12-02 |
| ➤ Subscribe | Gel | 1.2%/2.5% | ➤ Subscribe | 2012-12-20 |
| ➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2004-09-21 |
| ➤ Subscribe | Gel | 0.1% | ➤ Subscribe | 2010-07-08 |
| ➤ Subscribe | Ophthalmic Solution | 0.07% | ➤ Subscribe | 2013-07-26 |
| ➤ Subscribe | Capsules | 75 mg | ➤ Subscribe | 2011-06-06 |
| ➤ Subscribe | Vaginal Gel | 0.75% | ➤ Subscribe | 2004-09-02 |
| ➤ Subscribe | Cream | 5% | ➤ Subscribe | 2006-10-17 |
| ➤ Subscribe | Topical Solution | 10% | ➤ Subscribe | 2018-06-06 |
| ➤ Subscribe | Cream | 0.10% | ➤ Subscribe | 2008-01-31 |
International Patents for Bausch Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013005434 | ⤷ Try a Trial |
| Japan | 2016147908 | ⤷ Try a Trial |
| Japan | 2019081785 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bausch Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0427680 | SPC/GB03/015 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PIMECROLIMUS OR SALTS OR ESTERS THEREOF; REGISTERED: DK 21034 (MT-NO.32700) 20020315; UK PL 00101/0659 20021003 |
| 2822954 | 2018/031 | Ireland | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTRATION NO/DATE: EU/1/18/1289 20180625 |
| 0031058 | 98C0008 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
